A randomized trial evaluating a block-replacement regimen during radioiodine therapy.

摘要: Eur J Clin Invest 2010; 41 (7): 693–702 Abstract Background  Lack of consensus regarding the antithyroid drug regimen in relation to radioiodine (131I) therapy hyperthyroidism prompted this randomized trial comparing two strategies. Design  Patients with Graves’ disease (GD, n = 51) or toxic nodular goitre (TNG, n = 49) were 131I either 8 days following discontinuation methimazole (−BRT, n = 52, median dose: 5 mg) while on a continuous block-replacement (+BRT, n = 48, dose 15 mg and 100 μg levothyroxine). Results  +BRT group required more radioactivity. In group, thyroid function did not change early post period, serum-free T3 index was higher −BRT (P < 0·05). One year posttherapy, fraction cured patients (euthyroid hypothyroid) 48% 61% respectively (P = 0·014 unadjusted; P = 0·004 adjusted), but outcome depended type disease. GD, treatment failure correlated positively 24-h uptake (P = 0·017), no correlations existed group. addition allocation, TNG at risk lower radiation doses (P = 0·048), (P = 0·026) levels serum TSH (P = 0·009). Conclusions  A results stable during is hampered by amounts radioactivity required. The study demonstrates that GD highly unpredictable, number factors.